Marvin Schwickert
Overview
Explore the profile of Marvin Schwickert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
47
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fuchs N, Zimmermann R, Schwickert M, Gunkel A, Zimmer C, Meta M, et al.
ACS Infect Dis
. 2024 Apr;
10(5):1664-1678.
PMID: 38686397
In this study, we have identified and optimized two lead structures from an in-house screening, with promising results against the parasitic flatworm and its target protease cathepsin B1 (CB1). Our...
2.
Schwickert M, Zimmermann R, Habeck T, Hoba S, Nidoieva Z, Fischer T, et al.
ACS Med Chem Lett
. 2023 Jun;
14(6):777-787.
PMID: 37312859
The DNA methyltransferase 2 (DNMT2) is an RNA modifying enzyme associated with pathophysiological processes, such as mental and metabolic disorders or cancer. Although the development of methyltransferase inhibitors remains challenging,...
3.
Muller P, Meta M, Meidner J, Schwickert M, Meyr J, Schwickert K, et al.
Int J Mol Sci
. 2023 Apr;
24(8).
PMID: 37108388
Covalent peptidomimetic protease inhibitors have gained a lot of attention in drug development in recent years. They are designed to covalently bind the catalytically active amino acids through electrophilic groups...
4.
Zimmermann R, Fischer T, Schwickert M, Nidoieva Z, Schirmeister T, Kersten C
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047081
Targeting RNA methyltransferases with small molecules as inhibitors or tool compounds is an emerging field of interest in epitranscriptomics and medicinal chemistry. For two challenging RNA methyltransferases that introduce the...
5.
Zimmermann R, Schwickert M, Meidner J, Nidoieva Z, Helm M, Schirmeister T
ACS Pharmacol Transl Sci
. 2022 Nov;
5(11):1079-1085.
PMID: 36407957
Developing methyltransferase inhibitors is challenging, since most of the currently used assays are time-consuming and cost-intensive. Therefore, efficient, fast, and reliable methods for screenings and affinity determinations are of utmost...
6.
Schwickert M, Fischer T, Zimmermann R, Hoba S, Meidner J, Weber M, et al.
J Med Chem
. 2022 Jul;
65(14):9750-9788.
PMID: 35849534
Selective manipulation of the epitranscriptome could be beneficial for the treatment of cancer and also broaden the understanding of epigenetic inheritance. Inhibitors of the tRNA methyltransferase DNMT2, the enzyme catalyzing...
7.
Fischer T, Meidner L, Schwickert M, Weber M, Zimmermann R, Kersten C, et al.
Nucleic Acids Res
. 2022 Apr;
50(8):4216-4245.
PMID: 35412633
RNA methyltransferases (MTases) are ubiquitous enzymes whose hitherto low profile in medicinal chemistry, contrasts with the surging interest in RNA methylation, the arguably most important aspect of the new field...
8.
Barthels F, Barthels U, Schwickert M, Schirmeister T
SLAS Technol
. 2019 Sep;
25(2):190-199.
PMID: 31540570
3D-printed laboratory devices can enable ambitious research purposes even at a low-budget level. To follow this trend, here we describe the construction, calibration, and usage of the FINDUS (Fully Integrable...